In gastric cancer, doxorubicin-resistant cells that overexpress SHH and GLI1, the well-known signaling molecules involved in drug resistance, are susceptible to GLI inhibition with GANT61 and vismodegib via downregulation of its downstream effector ABCG2 [124]. This evidence concerns the gene GLI1 and gastric cancer.